Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jun;45(1-2):75-90.
doi: 10.1007/s10616-004-5127-z.

Targeting human telomerase for cancer therapeutics

Lionel Guittat  1 , Patrizia Alberti, Dennis Gomez, Anne De Cian, Gaëlle Pennarun, Thibault Lemarteleur, Chafke Belmokhtar, Rajaa Paterski, Hamid Morjani, Chantal Trentesaux, Eliane Mandine, François Boussin, Patrick Mailliet, Laurent Lacroix, Jean-François Riou, Jean-Louis Mergny
Affiliations

Targeting human telomerase for cancer therapeutics

Lionel Guittat et al. Cytotechnology. 2004 Jun.

Abstract

The enzyme telomerase is involved in the replication of telomeres, specialized structures that cap and protect the ends of chromosomes. Its activity is required for maintenance of telomeres and for unlimited lifespan, a hallmark of cancer cells. Telomerase is overexpressed in the vast majority of human cancer cells and therefore represents an attractive target for therapy. Several approaches have been developed to inhibit this enzyme through the targeting of its RNA or catalytic components as well as its DNA substrate, the single-stranded 3'-telomeric overhang. Telomerase inhibitors are chemically diverse and include modified oligonucleotides as well as small diffusable molecules, both natural and synthetic. This review presents an update of recent investigations pertaining to these agents and discusses their biological properties in the context of the initial paradigm that the exposure of cancer cells to these agents should lead to progressive telomere shortening followed by a delayed growth arrest response.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Akiyama M., Hideshima T., Shammas M.A., Hayashi T., Hamasaki M., Tai Y.T., Richardson P., Gryaznov S., Munshi N.C., Anderson K.C. Effects of oligonucleotide N3′->P5′ thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 2003;63:6187–6194. - PubMed
    1. Alberti P., Hoarau M., Guittat L., Takasugi M., Arimondo P.B., Lacroix L., Mills M., Teulade-Fichou M.P., Vigneron J.P., Lehn J.M., Mailliet P., Mergny J.L. Triplex vs. Quadruplex specific ligands and telomerase inhibition. In: Wilson D., editor. Small Molecule DNA and RNA Binders: From Synthesis to Nucleic Acid Complexes. Weinheim: Wiley-VCH; 2002a. pp. 315–336.
    1. Alberti P., Schmidt P., Nguyen C.H., Hoarau M., Grierson D., Mergny J.L. Benzoindoloquinolines interact with DNA quadruplexes and inhibit telomerase. Bioorg. Med. Chem. Lett. 2002b;12:1071–1074. doi: 10.1016/S0960-894X(02)00080-X. - DOI - PubMed
    1. Alberti P., Lacroix L., Guittat L., Hélène C., Mergny J.L. Nucleic acids as targets for antitelomerase agents. Mini Rev. Med. Chem. 2003;3:23–36. - PubMed
    1. Asai A., Oshima Y., Yamamoto Y., Uochi T., Kusaka H., Akinaga S., Yamashita Y., Pongracz K., Pruzan R., Wunder E., Piatyszek M., Li S.H., Chin A.C., Harley C.B., Gryaznov S. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 2003;63:3931–3939. - PubMed